**Detailed Summary of the Regulation: "Atomic Energy of Canada Limited Authorization Order, 1988"**

---

### **1. Regulatory Context and Legal Basis**

This regulation is a statutory order issued under the **Financial Administration Act (FAA)**, specifically pursuant to **subsection 101(6)** and **paragraphs 101(1)(a) and (b)**, along with **paragraph 108(2)(b)** of the FAA. These provisions empower the **Governor in Council** (i.e., the federal government, acting on the advice of key ministers) to authorize certain corporate actions involving government-owned entities, particularly when such actions are deemed necessary for public interest, economic efficiency, or strategic reallocation of assets.

- **Section 101(6)** of the FAA provides that the Governor in Council may authorize a corporation (such as Atomic Energy of Canada Limited – AECL) to incorporate another corporation and to hold or acquire shares in it.
- **Paragraphs 101(1)(a) and (b)** allow for the authorization of corporate actions where the government is acting in the public interest, especially when such actions support national objectives in science, technology, or economic development.
- **Paragraph 108(2)(b)** permits the disposal of government-owned assets (such as divisions or property) to newly incorporated entities, provided that the transfer serves a legitimate public purpose.

---

### **2. Purpose of the Order**

The primary purpose of this Order is to:

- Enable **Atomic Energy of Canada Limited (AECL)** — a Crown corporation under the *Canada Business Corporations Act* — to **incorporate a new company**, **Theratronics International Limited**, and to **hold or acquire shares** in that company.
- Facilitate the **transfer of assets** from AECL’s **Medical Products Division** to Theratronics International Limited.

This move reflects a strategic reorganization aimed at:
- Enhancing the commercial viability and market positioning of medical technologies developed by AECL.
- Separating the medical products business from AECL’s core nuclear energy operations to improve focus, accountability, and operational efficiency.
- Leveraging private-sector expertise and capital to advance innovation in medical devices, particularly in radiation therapy.

---

### **3. Key Provisions of the Order**

#### **(a) Authorization to Incorporate a New Corporation**
AECL is authorized to:
- Procure the incorporation of a new corporation named **Theratronics International Limited**.
- Upon incorporation, **all shares** of Theratronics International Limited will be:
  - Held by AECL, or
  - Held on behalf of AECL, or
  - Held in trust **for AECL**.

> This ensures that AECL maintains full ownership and control over Theratronics, even though it operates as a separate legal entity.

#### **(b) Authorization to Acquire Shares**
AECL is authorized to:
- Acquire shares in Theratronics International Limited.
- Upon acquisition, those shares will be held:
  - By AECL, or
  - On behalf of AECL, or
  - In trust for AECL.

> This provision allows AECL to fully integrate Theratronics into its corporate structure, ensuring that the new entity remains under AECL’s strategic and financial oversight.

#### **(c) Authorization to Dispose of Assets**
AECL is authorized to:
- **Sell or otherwise dispose of the property** of its **Medical Products Division** to Theratronics International Limited.

> This includes tangible and intangible assets related to the development, manufacturing, and distribution of medical devices — particularly those related to radiation therapy equipment such as linear accelerators and radiation treatment systems.

---

### **4. Legal and Governance Framework**

- **Corporate Status**: AECL is a corporation under the *Canada Business Corporations Act* (s. 181), which confirms its legal capacity to engage in corporate activities, including incorporation and shareholding.
- **Government Approval**: The Order was issued by the **Governor in Council**, acting on the **recommendation of the Minister of Energy, Mines and Resources** and the **Treasury Board**. This reflects a formal, policy-driven decision involving cross-departmental consultation and accountability.
- **Public Interest Justification**: The Order is grounded in the public interest, particularly in advancing Canada’s capabilities in medical technology and healthcare innovation.

---

### **5. Implications and Strategic Rationale**

- **Separation of Functions**: By spinning off the Medical Products Division into a standalone company, AECL can focus on its core business in nuclear energy and research, while Theratronics can operate independently to grow in the medical device market.
- **Commercialization of R&D**: AECL’s research in radiation therapy was being developed in-house. This order enables the commercialization of these technologies through a dedicated, market-focused entity.
- **Enhanced Innovation and Investment**: Theratronics could attract private investment, partnerships, and global market access, accelerating innovation in cancer treatment technologies.
- **Efficiency and Accountability**: A separate entity allows for better financial reporting, performance evaluation, and governance structures, which are critical for long-term success in the healthcare sector.

---

### **6. Citation and Legal Status**

- The Order is formally cited as:  
  **Atomic Energy of Canada Limited Authorization Order, 1988**  
  (S.C. 1984, c. 31, s. 11; S.C. 1978-79, c. 9, ss. 1(F), 57(1); S.C. 1974-75-76, c. 33(E); S.C. 1978-79, c. 9, s. 1(F))

> These references indicate that the Order is part of a broader legislative framework established over time to support the corporate governance and operational flexibility of AECL.

---

### **7. Conclusion**

This regulation represents a significant strategic reorganization within Canada’s nuclear and medical technology sector. It empowers AECL to:

- Establish a new, independent corporation (Theratronics International Limited) to commercialize its medical products.
- Fully own and control that corporation through shareholding and trust arrangements.
- Transfer its Medical Products Division’s assets to Theratronics, thereby enabling a more efficient, market-responsive, and innovative approach to healthcare technology development.

The Order is a classic example of government support for private-sector innovation through strategic asset transfer and corporate restructuring — balancing public accountability with private-sector growth.

--- 

**Note**: This Order is no longer in active force in its original form, as AECL and Theratronics have since undergone further restructuring. However, it remains historically significant as a foundational step in the commercialization of Canadian medical technologies.